VKTX
Viking Therapeutics Inc.
$34.81
+$2.44(+7.54%)
50
Overall
60
Value
60
Tech
31
Quality
Market Cap
$3.44B
Volume
6.21M
52W Range
$22.96 - $43.15
Target Price
$91.88
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $13.8M | $19.1M | $26.2M | $32.7M | $42.7M | $55.7M | $70.4M | $100.8M | $150.9M | $393.3M | ||
| Research & Development | $9.0M | $13.7M | $19.0M | $23.6M | $31.9M | $45.0M | $54.2M | $63.8M | $101.6M | $345.0M | ||
| Research Expense | $9.0M | $13.7M | $19.0M | $23.6M | $31.9M | $45.0M | $54.2M | $63.8M | $101.6M | $345.0M | ||
| Selling, General & Administrative | $4.8M | $5.3M | $7.1M | $9.1M | $10.7M | $10.7M | $16.1M | $37.0M | $49.3M | $48.4M | ||
| General & Administrative Expenses | $4.8M | $5.3M | $7.1M | $9.1M | $10.7M | $10.7M | $16.1M | $37.0M | $49.3M | $48.4M | ||
| Salaries & Wages | $-1.8M | $-1.5M | $-2.6M | $-3.7M | $5.8M | $6.1M | $8.7M | -- | -- | -- | ||
| Depreciation & Amortization | $1.8M | $1.3M | $404.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $1.8M | $1.3M | $404.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Amortization | $1.8M | $1.3M | $404.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | $319.0K | $320.0K | $340.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-15.6M | $-20.4M | $-26.6M | $-32.7M | $-42.7M | $-55.7M | $-70.4M | $-100.8M | $-150.9M | $-393.3M | ||
| EBITDA | $-12.7M | $-17.6M | $-20.8M | $-24.8M | $-42.4M | $-55.4M | $-90.6M | $-100.6M | $-150.6M | $-392.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $-15.0M | $-40.9M | $-33.7M | ||
| Intinc | $-21.9K | $1.0K | $3.2M | $7.0M | $3.2M | $703.0K | $1.6M | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-21.9K | $1.0K | $3.2M | $7.0M | $3.2M | $703.0K | $-1.5M | $15.0M | $40.9M | $33.7M | ||
| Gain on Sale of Securities | -- | -- | $-12.0K | $4.0K | $40.0K | -- | $-42.0K | -- | $112.0K | $55.0K | ||
| Other Income/Expense | $-925.5K | $226.0K | $-1.3M | $142.0K | $66.0K | $18.0K | $-42.0K | -- | $-112.0K | $-55.0K | ||
| Other Special Charges | $925.5K | $-226.0K | $1.3M | $-146.0K | $-106.0K | $-18.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-42.7M | $-55.7M | $-91.0M | $-100.9M | $-150.9M | $-393.3M | ||
| Pre-Tax Income | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.8M | $-109.9M | $-359.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $-9.5M | -- | -- | $-12.7M | $-17.5M | $-22.1M | -- | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | ||
| Net Income (Continuing Operations) | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | ||
| Net Income (Discontinued Operations) | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | ||
| Net Income (Common Stockholders) | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-356.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $13.8M | $19.1M | $26.2M | $32.7M | $42.7M | $55.7M | $70.4M | $100.8M | $150.9M | $393.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $16.3M | $26.0M | $57.6M | $72.0M | $72.6M | $77.2M | $76.8M | $94.3M | $109.0M | $112.7M | ||
| Average Shares Outstanding (Diluted) | $16.4M | $26.0M | $58.1M | $71.6M | $72.6M | -- | $76.8M | $94.3M | $109.0M | $112.7M | ||
| Shares Outstanding | $23.8M | $50.9M | $72.0M | $72.6M | $74.1M | $78.4M | $78.4M | $100.5M | $112.2M | $115.6M | ||
| Basic EPS | -- | -- | -- | -- | $-0.54 | $-0.71 | $-0.90 | $-0.91 | $-1.01 | $-3.19 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.54 | $-0.71 | $-0.90 | $-0.91 | $-1.01 | $-3.19 | ||
| Diluted EPS | $-0.90 | $-0.79 | $-0.38 | $-0.36 | $-0.54 | $-0.71 | $-0.90 | $-0.91 | $-1.01 | $-3.19 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-0.90 | $-0.91 | $-1.01 | $-3.19 | ||
| OTHER METRICS | ||||||||||||
| Minority Interests | -- | -- | -- | -- | $244.3M | -- | -- | -- | -- | -- | ||
| Other Gand A | $4.8M | $5.3M | $7.1M | $9.1M | $10.7M | $10.7M | $16.1M | $37.0M | $49.3M | $48.4M | ||
| Rent And Landing Fees | $4.8M | $5.3M | $7.1M | $9.1M | $319.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VKTX | $34.81 | +7.5% | 6.21M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Viking Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW